Patent
أعرض في EDS

Methods and compositions for screening for angiogenesis modulating compounds

التفاصيل البيبلوغرافية
العنوان: Methods and compositions for screening for angiogenesis modulating compounds
Patent Number: 7,196,190
تاريخ النشر: March 27, 2007
Appl. No: 09/738968
Application Filed: December 15, 2000
مستخلص: The present invention relates to novel transcription control elements, including promoters, derived from angiogenesis-related genes, particularly the mouse VEGF gene, the mouse VEGFR-2 receptor gene, and the mouse Tie2 gene. Also disclosed are isolated polynucleotides comprising such promoters, as well as nucleic acid constructs comprising such promoters operatively linked to genes encoding a gene product, such as, a reporter, a protein, polypeptide, hormone, ribozyme, or antisense RNA, and to recombinant cells and transgenic animals comprising such nucleic acid constructs. The present invention further relates to screening methods using those recombinant cells and transgenic animals, particularly methods of screening for therapeutic compounds that modulate tumorigenesis and angiogenesis.
Inventors: Ning, Zhang (Alameda, CA, US); Contag, Pamela Reilly (San Jose, CA, US); Purchio, Anthony F. (Alameda, CA, US)
Assignees: Xenogen Corporation (Alameda, CA, US)
Claim: 1. An isolated polynucleotide comprising either nucleotides 1 through 3,762 of SEQ ID NO:44 or a nucleic acid sequence that is at least 95% identical to the nucleotide sequence 1 through 3,762 of SEQ ID NO:44, wherein said isolated polynucleotide controls transcription of a gene operably linked thereto.
Claim: 2. An isolated polynucleotide consisting of either SEQ ID NO:44 or a nucleic acid sequence that is at least 95% identical to the sequence of SEQ ID NO:44, wherein said isolated polynucleotide controls transcription of a gene operably linked thereto.
Claim: 3. An expression cassette comprising: (a) the isolated polynucleotide of claim 1 comprising a transcription control element; and (b) a reporter sequence, operably linked to said transcription control element.
Claim: 4. The expression cassette of claim 3 , wherein said reporter sequence encodes a light-generating protein.
Claim: 5. An expression cassette comprising: (a) the isolated polynucleotide of claim 2 comprising a transcription control element; and (b) a reporter sequence, operably linked to said transcription control element.
Claim: 6. The expression cassette of claim 5 , wherein said reporter sequence encodes a light-generating protein.
Claim: 7. A vector comprising (a) the isolated polynucleotide of claim 1 comprising a transcription control element; (b) a reporter sequence, operably linked to said transcription control element; and (c) a vector backbone.
Claim: 8. The vector of claim 7 , wherein said reporter sequence encodes a light-generating protein.
Claim: 9. The vector of claim 7 , wherein said vector backbone comprises an origin of replication.
Claim: 10. The vector of claim 7 , wherein said vector is a shuttle vector.
Claim: 11. The vector of claim 7 , wherein said vector backbone further comprises a selectable marker.
Claim: 12. An isolated cell comprising the expression cassette of claim 3 .
Current U.S. Class: 536/241
Patent References Cited: 5650135 July 1997 Contag et al.
6020121 February 2000 Bao et al.
6217847 April 2001 Contag et al.
WO 94/11499 May 1994
WO 96/40979 December 1996
WO 9700957 January 1997
WO 97/11690 April 1997
WO 97/11690 April 1997
WO 97/18841 May 1997
WO 97/40381 October 1997
WO 98/28971 July 1998
WO 98/30715 July 1998
WO 98/55638 December 1998
WO 00/08726 February 2000
WO 00/36106 June 2000
WO 00/54581 September 2000
WO 00/54581 September 2000
WO 01/18195 March 2001
WO 01/18225 March 2001
WO 01/37195 May 2001
Other References: Shima et al. The mouse gene for vascular endothelial growth factor pp. 3877-3883 vol. 271, No. 7 1996. cited by examiner
Aiello et al., “Suppression of Retinal Neovascularization Iin Vivo by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins,” Proc. Natl. Acad. Sci. U.S.A. 92:10457-10461 (1995). cited by other
Asahara et al., “Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological Neovascularization,” Circ. Res. 85:221-228 (1999). cited by other
Bais et al., “G-Protein-Coupled Receptor of Kaposi's Sarcoma-Associated Herpes Virus is a Viral Oncogene and Anglogenesis Activator,” Nature 391:86-89 (1998). cited by other
Benjamin et al., “Conditional Switching of Vascular Endothelial Growth Factor (VEGF) Expression in Tumors: Induction of Endothelial Cell Shedding and Regression of Hemangioblastoma-Like Vessels by VEGF Withdrawal,” Proc. Natl. Acad. Sci. U.S.A. 94:8761-8766 (1997). cited by other
Berse, B., “Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophases, and Tumors,” Molecular Biology of the Cell 3:211-220 (1992). cited by other
Contag et al., “Visualizing Gene Expression Living Mammals Using a Bioluminescent Reporter,” Photochemistry and Photobiology 66(4):523-531 (1997). cited by other
Disalvo et al., “Purification and Characterization of Naturally Occurring Vascular Endothelial Growth Factor-Placenta Growth Factor Heterodimer,” The Journal of Biological Chemistry 270(13):7717-7723 (1995). cited by other
Dumont, et al., “Dominant-Negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, Tek, Reveal a Critical Role in Vasculogenesis of the Embryo,” Genes & Development 8:1897-1909 (1994). cited by other
Dvorak et al., “Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels,” J. Exp. Med. 174:1275-1278 (1991). cited by other
Ferrara et al., “The Biology of Vascular Endothelial Growht Factor,” Endocr. Rev. 18:(1):4-25 (1997). cited by other
Ferrara et al., “Heterozygous Embryonic Lethality Inducted by Targeted Inactivation of the VEGF Gene,” Nature 380:439-442 (1996). cited by other
Fong et al., “SU5416 Is a Potent and Selective Inhibitor of the Vascular Endothelial Growth Factor Receptor (Flk-1/KDR) That Inhibits Tyrosine Kinase Catalysis, Tumor Vascularization, and Growth of Multiple Tumor Types,” Cancer Research 59:99-106 (1999). cited by other
Forsythe et al., “Activation of Vascular Endothelial Growth Factor Gene Transcription by Hypoxia-Inducible Factor 1,” Molecular and Cellular Biology 16(9):4604-4613 (1996). cited by other
Fukumura et al., “Tumor Induction of VEGF Promoter Activity in Stormal Cells,” Cell 94:715-725 (1998). cited by other
Hanahan, D., “Signaling Vascular Morphogenesis and Maintenance,” Science 277:48-50 (1997). cited by other
Ikeda et al., “Hypoxia-Induced Transcriptional Activation and Increased mRNA Stability of Vascular Endothelial Growth Factor in C6 Glioma Cells,” The Journal of Biological Chemistry 270(34):19761-19765 (1995). cited by other
Jain, R.K., “Endothelial Cell Death, Augiogenesis, and Microvascular Function After Casteration in an Andgrogen-Dependent Tumor: Role of Vascular Endothelial Groth Factor,” Proc. Natl. Acad. Sci. U.S.A. 95:10820-10825 (1998). cited by other
Jeltsch et al., “Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice,” Science 276:1423-1425 (1997). cited by other
Kaipainen, et al., “Enhanced Expression of the Tie Receptor Tyrosine Kinase Messenger RNA in the Vascular Endothelium of Metastatic Melanomas,” Cancer Research 54:6571-6577 (1994). cited by other
Kappel et al., “Identification of Vascular Endothelial Growth Factor (VEGF) Receptor-2 (Flk-1) Promother/Enhancer Sequences Sufficient for Angioblast and Endothelial Cell-Specific Transcription in Transgenic Mice,” Blood 93(12):4284-4292 (1999). cited by other
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo,” Nature 362:841-844 (1993). cited by other
Kitsukawa et al., “Overexpression of Membrane Protein, Neuropilin, in Chimeric Mice Causes Anomalies in the Cardiovascular System, Nervous System and Limbs,” Development 121:4309-4318 (1995). cited by other
Larcher et al., “VEGF/VPF Overexpression in Skin of Transgenic Mice Induces Angiogenesis, Vascular Hyperpermeability and Accelerated Tumor Development,” Oncogene 17:303-311 (1998). cited by other
Millauer, B., “High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenes,” Cell 72:835-846 (1993). cited by other
Millauer, B., “Glioblastoma Growth Inhibited In Vivo by a Dominant-Negative Flk-1 Mutant,” Nature 367:576-579 (1994). cited by other
Millauer, B., “Dominant-Negative Inhibition of Flk-1 Suppresses the Growth of Many Tumor Types In Vivo,” Cancer Res. 56:1615-1620 (1996). cited by other
Mukhopadhyay et al., “Wild-Type p53 and v-Src Exert Opposing Influences on Human Vascular Endothelial Growth Factor Gene Expression,” Cancer Res. 15:6161-6165 (1995). cited by other
Mukhopadhyay et al., “Hypoxic Induction of Human Vascular Endothelial Growth Factor Expression Through c-Src Activation,” Nature 375:577-581 (1995). cited by other
Oh et al., “VEGF and VEGF-C: Specific Induction of Angiogenesis and Lyphangiogenesis in the Differentiated Avian Chorioallantoic Membrane,” Developmental Biology 188:96-109 (1997). cited by other
Okamoto et al., “Transgenic Mice With Increased Expression of Vascular Endothelial Growth Factor in the Retinal,” American Journal Pathology 151:281-291 (1997). cited by other
Olofason et al., “Vascular Endothelial Growth Factor B, a Novel Growth Factor for Endothelial Cells,” Proc. Natl. Acad. Sci. U.S.A. 93:2576-2581 (1996). cited by other
Patterson et al., “Cloning and Functional Analysis of the Promoter for KDR/flk-1, a Receptor for Vascular Endothelial Growth Factor,” The Journal of Biological Chemistry 270(39):23111-23118 (1995). cited by other
Plate et al., “Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas In Vivo,” Nature 359:845-848 (1992). cited by other
Plate et al., “Up-Regulation of Vascular Endothelial Growth Factor and Its Cognate Receptors in a Rat Glioma Model of Tumor Angiogenesis,” Cancer Research 53:5822-5827 (1993). cited by other
Puri et al., “The Receptor Tyrosine Kinase TIE is Required for Integrity and Survival of Vascular Endothelial Cells,” EMBO Journal 14(23):5884-5891 (1995). cited by other
Rönicke et al., “Characterization of the Endothelium-Specific Murine Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter,” Circulation Research 79(2):277-285 (1996). cited by other
Shalaby et al., “Failure of Blood-Island Formation and Vasculogenesis in Flk-1-Deficient Mice,” Nature 376:62-65 (1995). cited by other
Shweiki et al., “Vascular Endothelial Growth Factor Induced by Hypoxia may Mediate Hypoxia-Initiated Angiogenesis,” Nature 359:843-845 (1992). cited by other
Shweiki et al., “Induction of Vascular Endothelial Growth Factor Expression by Hypoxia and by Glucose Deficiency in Multicell Spheroids: Implications for Tumor Angiogenesis,” Proc. Natl. Acad. Sci. U.S.A. 92:768-772 (1995). cited by other
Siemeister et al., “An Antagonistic Vascular Endothelial Growth Factor (VEGF) Variant Inhibits VEGF-Stimulated Receptor Autophosphorylation and Proliferation of Human Endothelial Cells,” Proc. Natl. Acad. Sci. U.S.A. 95:4625-4629 (1998). cited by other
Soker et al., “Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor,” Cell 92:735-745 (1998). cited by other
Soker et al., “Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells that Bind VEGF 165 Via Its Exon 7-Encoded Domain,” Journal of Biological Chemistry 271:5761-5767 (1996). cited by other
Soker et al., “Inhibition of Vascular Endothelial Growth Factor (VEGF)-Induced Endothelial Cell Proliferation by a Peptide Corresponding to the Exon 7-Encoded Domain of VEGF 165,” Journal of Biological Chemistry 272(50):31582-31588 (1997). cited by other
Stratmann A., “Cell Type-Specific Expression of Angiopoietin-1 and Angiopoietin-2 Suggests a Role in Glioblastoma Angiogenesis,” American Journal of Pathology 153(5):1459-1466 (1998). cited by other
Suri et al., “Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, During Embryonic Angiogenesis,” Cell 87:1171-1180 (1996). cited by other
Takahashi et al., “Markedly Increased Amounts of Messenger RNAs for Vascular Endothelial Growth Factor and Placenta Growth Factor in Renal Cell Carcinoma Associated with Angiogenesis,” Cancer Res. 54:4233-4237 (1994). cited by other
Terman et al., “Identification of a New Endothelial Cell Growth Factor Recptor Tyrosine Kinase,” Oncogene 6(9):1677-1683 (1991). cited by other
Tischer et al., “The Human Gene for Vascular Endothelial Growth Factor,” Journal of Biological Chemistry: 266 (18):11947-11954 (1991). cited by other
Waltenberger, J., “Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor,” Journal of Biological Chemistry 269(43):26988-26995 (1994). cited by other
Yoshiji et al., “Vascular Endothelial Growth Factor is Essential for Initial but not Continued in Vivo Growth of Human Breast Carcinoma Cells,” Center Research 57:3924-3928 (1997). cited by other
Yuan et al., “Time-Dependent Vascular Regression and Permeability Changes in Established Human Tumor Xenografts Induced by an Anti-Vascular Endothelial-Growth Factor/Vascular Permeability Factor Antibody,” Proc. Natl. Acad. Sci. U.S.A. 93:14765-14770 (1996). cited by other
Primary Examiner: Nguyen, Quang
Attorney, Agent or Firm: Robins & Pasternak LLP
رقم الانضمام: edspgr.07196190
قاعدة البيانات: USPTO Patent Grants
الوصف
الوصف غير متاح.